Navigation Links
FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Date:3/19/2008

BOSTON, March 19 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Dr. Alan Fischman, Professor of Radiology at Harvard Medical School and former Director of the Nuclear Medicine Division at Massachusetts General Hospital. BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials.

BFPET is a PET blood flow imaging agent, for use in classic "rest-stress" cardiac testing. More than 9 million Americans each year undergo myocardial perfusion imaging, the standard test to assess coronary artery disease (CAD). BFPET, as a PET imaging tracer, may have a significant advantage due to its potential to improve the sensitivity and specificity of CAD diagnosis and to provide information on myocardial mitochondrial damage. "This agent, if successful, should improve CAD diagnosis and follow-up of therapy and intervention, and broaden the utility of PET as an imaging modality," said Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder. "BFPET has performed well in animals with a target-to-blood ratio of 70:1, and we look forward to evaluating the agent in human studies."

"We are delighted to have our second product enter clinical trials," said Dr. Ljiljana Kundakovic, FluoroPharma's President. "BFPET's progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the heart, which recently completed a Phase I safety evaluation in normal healthy volunteers and cardiac patients. FluoroPharma has the potential to significantly impact diagnos
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
3. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... 21, 2015 Research and ... of the "Market Assessment of Respiratory Diagnostics ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This ... imaging diagnostics market in the United ... . The service provides detailed analysis of the ...
(Date:5/21/2015)...  (MUSE Booth # 1510)What:Automating continuous vital sign ... invaluable in any hospital setting, but particularly for ... and mainstream in healthcare, the integration of data ... gaining traction in MEDITECH facilities.During MUSE 2015 (Medical ... Manager & Clinical Analyst at McLaren Huron Hospital, ...
(Date:5/21/2015)...  Heidrick & Struggles (Nasdaq: HSII ), the ... consulting and culture shaping worldwide, strengthens ... announcing the addition of Tim Dietlin to ... Dietlin has extensive life sciences and professional ... Medical and Commercial functions to increase productivity, drive transformational ...
Breaking Medicine Technology:United States and Europe Respiratory Diagnostics Market Assessment 2015 2Hospital Streamlines ICU Efficiency with Timely Data Integration 2Hospital Streamlines ICU Efficiency with Timely Data Integration 3Heidrick Increases Healthcare and Life Sciences Expertise 2
... Inc. announced today that it will present four,posters on ... which will be held at the San,Diego Convention Center ... 2007. , The following posters will be presented on ... San Diego Convention Center (Sails,Pavilion, Upper Level). , POSTER ...
... chemotherapy significantly,increases patients_ overall survival , BASEL, ... study published,yesterday in the Journal of Clinical ... to significantly improve,survival in patients with follicular ... is the most common type of,indolent lymphoma, ...
Cached Medicine Technology:Vanda Pharmaceuticals to Present Data on Iloperidone at the 2007,American Psychiatric Association Annual Meeting 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 2Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 3Innovative Cancer Drug MabThera Again Shown To Improve Survival,Rates In Patients With Lymphoma 4
(Date:5/23/2015)... IL (PRWEB) May 23, 2015 A live ... medical equipment from hospitals, surgery centers and other medical facilities ... be sold including endoscopy, lab, radiology, surgery, anesthesia, exam and ... Wednesday, May 27 and Thursday, May 28 starting at 9:00am ... located at 1400 N. 25th Avenue, Melrose Park, IL 60160. ...
(Date:5/22/2015)... 2015 The world is at ... are intersecting to create new opportunities for leadership ... speaker at WesternU's 34th annual Commencement Exercises said ... Newsom, a former San Francisco mayor and likely ... the graduation ceremony for WesternU's colleges of Allied ...
(Date:5/22/2015)... River Valley Health Partners (RVHP) Board ... system’s Chief Financial Officer (CFO), will be leaving the ... the company CFO since 2011. , The Board of ... health system as CFO. Wesley will oversee the health ... Board of Trustees conducts a formal search for a ...
(Date:5/22/2015)... Combination therapy, or polytherapy, will likely ... pulmonary disorder (COPD) as the dominant companies like ... well as Germany’s Boehringer Ingelheim compete with each ... market payers, clinicians and patients be disposed to ... new ones? , In spite of recently approved ...
(Date:5/22/2015)... 2015 Carnegie Science Center ... a new partnership to develop BodyTech, a dynamic, three-pronged ... initiative includes a new exhibit at the Science Center ... and a new traveling science show, Anatomy Adventure, which ... , Designed to explore a wide range of ...
Breaking Medicine News(10 mins):Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2Health News:Newsom to WesternU Grads: The Future is Inside You 2Health News:Newsom to WesternU Grads: The Future is Inside You 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... American Cancer Society study of twelve types of cancer ... patients were significantly more likely to present with advanced ... study, which appears in the March issue of The ... to investigate insurance status and stage of diagnosis for ...
... es Salaam, Tanzania, WASHINGTON, Feb. 17 , 1:35 ... dear wife -- Mr.,President, welcome again to Amana Hospital. Well, ... for PEPFAR, the President,s,Emergency Plan for AIDS Relief., Through ... a,facility we just visited, and again, this clinic. In Dar ...
... Month, , , SUNDAY, Feb. 17 (HealthDay News) ... Americans about age-related macular degeneration (AMD), Prevent Blindness ... Month. , AMD -- a progressive disease that ... $570 million a year in direct costs for ...
... that a new wave of drug-resistant HIV is rising among among ... this trend will continue over the next few years, according to ... , At the same time, the evolution of drug-resistant HIV may ... men from becoming infected. , The model and ...
... The public health problem that needs to be addressed ... physicians who have come together to discuss the latest in ... the American Academy of Pain Medicine (AAPM), February 12-16 at ... decades, Americans, with the help of their physicians, have been ...
... people with depression , , SATURDAY, Feb. 16 (HealthDay News) -- ... syndrome (IBS) in adults, says a study by researchers at ... about 15 percent of the U.S. population. Some studies have ... some patients, but the frequency hadn,t been examined. , In ...
Cached Medicine News:Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Don't Lose Sight of Vision Care, Group Urges 2Health News:Novel mathematical model predicts new wave of drug-resistant HIV infections in San Francisco 2Health News:Physicians focus on stopping pain epidemic 2Health News:Physicians focus on stopping pain epidemic 3Health News:Physicians focus on stopping pain epidemic 4Health News:Physicians focus on stopping pain epidemic 5Health News:Physicians focus on stopping pain epidemic 6Health News:Allergy Disorders Linked With Irritable Bowel Syndrome 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: